Scientific progress and company updates

Dr. Rajesh Chopra joins Numab with nearly four decades of experience spanning oncology, immunology, translational medicine, and drug development, having held leadership roles across biotechnology, pharma, venture creation, and academic research. His scientific expertise and track record of bringing innovative therapies from discovery through development will guide the company's scientific strategy and pipeline progression.

Numab to receive milestone payment. Boehringer Ingelheim has advanced its novel multi-specific antibody for retinal diseases resulting from a collaboration with Numab into preclinical development.

Kaken Pharmaceutical in-licenses NM81 across select Asian territories and commits to funding global development into the clinic.

Boehringer Ingelheim has advanced its novel tumor antigen targeting T cell engager resulting from a a collaboration with Numab into preclinical development.

Numab Therapeutics announces that David Urech, Ph.D., Chief Executive Officer and co-founder of Numab, will transition from his position as CEO and continue as a member of the Board of Directors and Chair of the R&D Committee. As part of the planned leadership transition, Numab has appointed industry veteran Barbara Angehrn Pavik as CEO and member of the Board, effective immediately.

Proceeds will be used to support the advancement of multiple first-in-class and best-in-class programs into clinical development.

Numab to receive R&D funding for the preclinical development of ND081. Kaken Pharmaceutical receives an option to in-license ND081 in certain Asian territories in exchange for funding global development up to clinical POC.

NM32 is a first-in-class half-life-enhanced T-cell engager targeting ROR1, a tumor associated antigen with broad expression in solid tumors and hematological malignancies. Low molecular weight of NM32 allows to efficiently achieve higher tumor concentrations than larger immunoglobulin G molecules, the current standard format for CD3 engagers.

J&J will gain full rights to develop, manufacture and commercialize NM26 globally for the treatment of atopic dermatitis and follow-on indications. Under the agreement terms, J&J will pay $1.25 billion to acquire Yellow Jersey Therapeutics, which holds NM26 rights. NM26 is a Phase 2-ready bi-specific antibody from Numab’s pipeline of candidates discovered and engineered using its proprietary MATCH™ technology platform.

NM49 is a multi-specific antibody identified through Numab’s proprietary discovery and engineering technology platform designed to activate tumor associated macrophage phagocytosis. Numab to receive upfront payment and eligible to receive additional milestone payments plus option to co-develop with profit split arrangement in the United States. Agreement marks third collaboration agreement between Numab and Ono Pharmaceutical.

NM26 is a first-in-class bi-specific antibody designed to simultaneously block multiple targets, targeting the underlying inflammation as well as the neuroinflammatory pathway that causes itch.

Numab Therapeutics AG announced today that the first subject has been dosed in the Phase 1 clinical study of NM26-2198, a first-in-class bi-specific antibody for the treatment of moderate-to-severe atopic dermatitis (AD).

Numab Therapeutics AG and Ono Pharmaceutical Co., Ltd. today announced that Ono has exercised its option to enter into a development and license agreement for a multispecific antibody candidate that was generated through a research collaboration between the two companies initiated in 2017.

Numab Therapeutics AG and 3SBio Inc. announced today that 3SBio’s subsidiary Sunshine Guojian exercised its option for an exclusive regional license for the development and commercialization of NM28, a potential best-in-class bivalent mesothelin (MSLN)-targeting CD3 T cell engager.

Numab Therapeutics AG today announced the closing of a CHF 100 million (approximately USD 110 million) Series C financing. The financing was co-led by new investors Novo Holdings and HBM Partners, with participation from additional new investors Forbion via its Forbion Growth Opportunities Fund, Cormorant Asset Management, BVF Partners L.P., RTW Investments L.P., funds and accounts under the management of BlackRock, Octagon Capital Advisors, and existing investors.

Numab Therapeutics AG today announced the formation of a global co-development and regional licensing agreement with Kaken Pharmaceutical for the company’s novel multispecific anti-inflammatory drug candidate NM26-2198, which blocks three key pathways in the pathophysiology of atopic dermatitis. The alliance builds on a collaboration and option agreement established in 2017.

Numab Therapeutics AG announced today the appointment of Dr. med. Daniel Vasella, former Chairman and Chief Executive Officer of Novartis AG, as the new and independent Chairman of the Board of Numab. Dr. Vasella succeeds Dr. Oliver Middendorp, founder and current Chief Business Officer, who remains on the Board of Directors as a regular member.

Numab Therapeutics AG announced today the first patient has been dosed in its proprietary ND021 program, a next-generation tri-specific immuno-oncology approach targeting PD-L1, 4-1BB and Serum Albumin. The study will initially enroll up to 102 cancer patients at four major clinical sites across the United States and Taiwan and will expand to additional centers as the study progresses. In its first part, this international, multi-center Phase 1/2 clinical study will investigate the safety and tolerability of ascending doses of NM21-1480, the company’s clinical lead molecule in the ND021 program, in patients with various forms of solid tumors and establish a recommended dose for continued clinical development. The trial will subsequently explore the anti-tumor activity of the compound in patients suffering from selected tumor types.

Numab Therapeutics and Boehringer Ingelheim today announced that they have entered into a research collaboration and worldwide licensing agreement. It will start with two projects aiming at novel therapies for difficult-to-treat lung and gastrointestinal (GI) cancers and patients with geographic atrophy (GA), a progressive, irreversible retinal disease that occurs in patients with age-related macular degeneration (AMD) for which there is no current treatment. The collaboration brings together Boehringer Ingelheim’s leading expertise in the research and development of life-changing breakthrough therapies with Numab’s multi-specific antibody platform. Lung and GI cancers and retinal diseases are key focus areas of Boehringer Ingelheim’s research and development program. In oncology the company has built a broad and diverse pipeline, combining cancer immunology and cancer cell-directed approaches. The novel T-cell engager to be developed with Numab adds to Boehringer Ingelheim’s growing cancer immunology portfolio and supports the strategy to take cancer on by targeting ‘cold’ tumors with synergistic combination approaches. In retinal diseases, Boehringer Ingelheim is pursuing a holistic approach leveraging existing expertise in oncology, inflammation, neurodegeneration, fibrosis and cardiometabolic diseases. The new GA program with Numab further broadens the company’s comprehensive portfolio of next-generation retinal therapy approaches in various stages of development up to Phase 2 in macular degeneration and diabetic retinal diseases.

Numab announced today an expansion of its relationship with Ono Pharmaceutical Co., Ltd. by executing another research and option agreement to discover and develop a multi-specific antibody drug candidate for the treatment of various cancers. Similar to their earlier collaboration initiated in March 2017, under this new agreement, Ono has obtained an option to acquire from Numab exclusive rights to develop and commercialize an immuno-oncology drug candidate that will leverage Numab’s platform technology in order to actualize one of Ono’s novel therapeutic approaches. In exchange, Ono will pay to Numab up to CHF 260 million in upfront and milestone payments plus tiered single to double-digit royalties on sales.

Numab Therapeutics AG announced today the closing of its Series B financing round at a total volume of CHF 22M (approximately USD 22.6M). New investors in this round included 3SBio/Sunshine Guojian, Mitsubishi UFJ Capital Co., Ltd. and Eisai Co., Ltd. as well as Numab’s board member Dr. Daniel Vasella. Existing shareholders that participated in Numab’s Series A round also contributed to today’s financing. With the financing secured, Numab plans to further broaden its proprietary pipeline and accelerate the development for a number of programs towards the clinic. The company also plans to initiate a clinical trial for its lead oncology program ND021 during the course of 2020.

Numab Therapeutics AG today announced a partnership with 3SBio’s subsidiary Sunshine Guojian Pharmaceutical focusing on the development and commercialization of a portfolio of novel multi-specific cancer antibodies. As part of the alliance, Sunshine Guojian has invested CHF15M (approximately USD 15.2M) in Numab’s series B financing.

Wädenswil, Switzerland, October 15, 2019 – Numab Therapeutics AG today announced that effective October 1 it has appointed former Novartis CEO and Chairman Dr. Daniel Vasella to its Board of Directors.

ZURICH, SWITZERLAND, October 1, 2019 – Numab Therapeutics AG (Numab) today announced the initiation of a partnership with Eisai, Co., Ltd (Eisai), under a research and option agreement, to discover and develop novel multi-specific antibody immunotherapies for cancer, using Numab’s proprietary MATCH™ platform.

Pfäffikon SZ, Switzerland May 2, 2019 – CStone Pharmaceuticals (HKEX: 2616) and Numab Therapeutics AG today announce that they have entered into an exclusive regional licensing agreement for the development and commercialization of ND021, a potential best-in-class monovalent, tri-specific antibody-based molecule targeting PD-L1, 4-1BB, and human serum albumin (HSA).

Numab delivered a poster presentation today, providing new animal data on its lead I/O drug candidate, NM21-1480, emerging from the company’s ND021 program. NM21-1480 is a PD-L1/4-1BB/HSA trispecific scMATCH3 that simultaneously blocks PD-(L)1 signaling and conditionally costimulates 4-1BB+ cells in the tumor microenvironment. The unique properties of NM21-1480 enables best-in-class antitumoral efficacy while avoiding extratumoral activity and thereby preventing any 4-1BB-mediated toxicities. Studies in mice and non-human primates support NM21-1480 as a safe and highly effective drug candidate for a variety of cancers.

Pfäffikon, Switzerland, March 5, 2019 – Numab Therapeutics AG today announced that Intarcia Therapeutics Inc. has executed its option to in-license ND016, being developed for the treatment of autoimmune disorders. Numab discovered ND016 on behalf of Intarcia under a previous research and option agreement. Under the present exclusive license agreement, Intarcia receives worldwide rights to develop and commercialize ND016 in exchange for license payments of up to CHF 70 million and up to double digit tiered royalties on net sales.

Numab Therapeutics AG, a biopharmaceutical company developing next-generation multispecific antibody-based immunotherapies for cancer, today announced the appointments of Prof. Mario Sznol from Yale Cancer Center and Prof. David Hong from the MD Anderson Cancer Center to its clinical advisory board. They will join Dr. Ignacio Melero who was appointed in September last.

Numab Therapeutics AG, a biopharmaceutical company developing next-generation multispecific antibody-based immunotherapies for cancer, today announced it appointed Dr. Ignacio Javier Melero Bermejo as scientific advisor. Ignacio Melero, M.D., Ph.D., is professor of immunology at the Academic Hospital of Navarra and at the Center for Applied Medical Research (CIMA) of the University of Navarra. He leads a group working in translational tumor immunotherapy with emphasis on cell therapy, cytokine gene therapy, and immune-stimulatory monoclonal antibodies.

Numab Therapeutics AG today presents preclinical efficacy data for its immuno-oncology lead product ND021 at the Annual Meeting of the American Association for Cancer Research (AACR). ND021 is a trispecific molecule that simultaneously targets PDL1 on cancer and a costimulatory receptor on T cells. The preclinical data presented today confirm the differentiating potential of ND021 in terms of efficacy and safety over PD-1/PDL1 blocking agents and their combination with antibodies targeting the costimulatory receptor. Please click on the link below to download the AACR poster presentation.

Intarcia Therapeutics, Inc., and Numab Therapeutics AG today announced the achievement of a key milestone in their on-going development partnership – the selection of a multi-specific antibody construct targeting autoimmune and inflammatory diseases. This delivery marks the first major milestone in the strategic relationship, established in the spring of 2015, and triggers a payment to Numab that will bring the total payments for this project to CHF 11.5 million to date.

Numab Therapeutics AG (“Numab”) today announced a collaboration and option agreement with Kaken Pharmaceutical Co., Ltd. (“Kaken”) for the identification of a multispecific antibody candidate for development in inflammatory disease. Under the agreement, Kaken will obtain an option to conclude a license and co-development agreement after identification of lead candidate generated by Numab using its unique multispecific antibody technology platform. Kaken is to fully fund the research program.

Numab Therapeutics AG (“Numab”) today announced a research and option agreement with Ono Pharmaceutical Co., Ltd. (“Ono”) for the identification of a multi-specific antibody candidate for development in immunooncology.

Intarcia Therapeutics, Inc., and Numab AG, today announced the achievement of several key milestones in the development of a multi-specific antibody targeting inflammatory / autoimmune diseases. This is an important step towards realizing the potential of combining Numab’s antibody- based therapeutics with Intarcia’s unique delivery and formulation technologies. Read more in the PDF below.

Tillotts Pharma AG (“Tillotts”) and Numab AG announced today that they have entered into an exclusive global licensing agreement to develop and commercialize new antibody-based therapies that act against tumor necrosis factor alpha (TNF-α) for people with inflammatory bowel disease (IBD). The partnership demonstrates Tillotts’ commitment to developing new treatments to improve care for patients with IBD and, upon successful development, will add to a strong track record in the registration and marketing of IBD treatments globally. Read more in the PDF below.

Intarcia Therapeutics, Inc. and Numab AG today announced a strategic collaboration focused on the development of once- or twice-yearly mono-specific and multi-specific antibodies addressing diabetes, obesity and autoimmune indications. Read more in the PDF below.

Numab AG, a company focused on the discovery and development of antibody based therapeutics announced today that they have received a milestone payment under a collaboration that was initiated in February 2013. Read more in the PDF below.

Numab AG, a company focused on the discovery and development of innovative antibody-based therapeutics, announced today that it has reacquired the rights to ND003, a bispecific anti-IL5RxCD3 antibody fragment for the targeted lysis of eosinophils in severe asthma, from Sucampo AG, a subsidiary of Sucampo Pharmaceuticals, Inc. (Nasdaq:SCMP). Read more in the PDF below.

Numab AG, a Swiss biotech company, announces the appointment of Dr. Robert Kamen to its Advisory Board. Dr. Kamen has more than 30 years of experience in the pharmaceutical and biotechnology industry, including leadership roles at Abbott Bioresearch Center and Genetics Institute. He is also a co-founder of BioAssets Development Corporation and has held advisory and board positions with several biopharmaceutical companies. Dr. Kamen brings extensive experience in therapeutic antibody discovery and development to Numab’s Advisory Board.

Numab AG, a Swiss biotech company focused on the discovery and development of innovative antibody-based therapeutics, announces the successful selection of an antibody fragment lead as part of its ongoing multi-target collaboration with Sucampo AG. The achievement of this milestone triggered a CHF 3 million success payment to Numab under the collaboration agreement with Sucampo AG concluded and announced on September 8, 2011. Read more in the PDF below.

Numab AG, a Swiss Biotech company, today announces the appointment of Prof. Burkhard Becher to Numab’s Scientific Advisory Board. Burkhard Becher is a world leading immunologist, whose research aims at understanding the development of tissue-specific autoimmunity, tumor immunology and cytokine biology. In 2003, he was recruited as Assistant Professor to the University Hospital of Zurich and in 2008, he became full professor and co-chair at the Institute of Experimental Immunology at the University of Zurich. His fundamental contribution to the field has been published in the leading scientific journals. Most recently he was awarded the Robert Bing Price for Neuroscience, the Biogen Dompé MS-Research Price and the Prof. Max Cloëtta Award, adding to the various honors he has received for his scientific work. Read more in the PDF below.

Numab AG, a Swiss Biotech company, today announces that it has been awarded the “CTI Start-up Label” from the Swiss Commission for Technology and Innovation (CTI) only one year after inception of the Company. With this award the CTI acknowledges that Numab is professionally developed and has a sound basis for sustained future growth. As a condition for this award Numab successfully past a formal due diligence, performed by external experts, on the practicability of Numab’s innovative technology, the associated intellectual property rights, as well as the Company’s business model and financials. The CTI supports creative entrepreneurs to realize their innovative business ideas. More than 85 percent of the companies that were awarded the CTI start-up label in the past 10 years turned into commercially successful businesses, and some are regarded as “stars” of the Swiss entrepreneur scene. Read more in the PDF below.

Numab AG, a Swiss Biotech company, today announces the approval of a research grant from the Swiss Commission for Technology and Innovation (CTI). The CTI supports Numab’s research on antibody-based approaches for the therapy of ion channel-driven health disorders with a grant of CHF 895’000. Numab is conducting the research activities within this project in collaboration with the Zürich University of applied Sciences (ZHAW). Read more in the PDF below.

Numab AG, a Swiss Biotech company, today announces the completion of its Management team with:Tea Gunde – Head of Pharmacology, Sebastian Meyer – Head of Biochemistry, Roland Helfenstein – Head of Operations. David Urech, CSO and Co-CEO and Oliver Middendorp, CBO and Co-CEO commented: “The people are the basis for success. We are very proud about the completion of our management with these highly experienced and ambitious people. We are convinced that this team will make Numab a success”.

Numab AG, a Swiss Biotech company, today announces the appointment of Dr Fritz Kunz as Chairman of the Board. Dr Kunz started his career in 1971 at Sandoz, where he held numerous positions in R&D management. In 1992, Fritz Kunz became CFO at Stratec Medical. From 1994 to 1998, he was CEO and a member of the Board of Directors of Institute Straumann. In 1998 Fritz Kunz became a member of the Board of Directors of Speedel, which he chaired from 2000 to 2008 when the company was acquired by Novartis. He is also the Chairman of Kuros and a member of the Board of Sentec. Read more in the PDF below.

Sucampo Pharmaceuticals, Inc. (NASDAQ: SCMP), an international pharmaceutical company, and Numab AG today announced that Sucampo’s wholly owned subsidiary, Sucampo AG, and Numab AG, have entered into a research and development collaboration that provides Sucampo with access to Numab’s proprietary technology for the discovery of high-affinity antibodies against certain selected targets. Sucampo will have exclusive commercial rights to any biologic products successfully developed and commercialized in the course of the collaboration. Read more in the PDF below.